Table 2.
Disease activity levels at baseline and nine and 18 month follow-up
| Dose reduction (n=121) | Usual care (n=59) | P* | |
|---|---|---|---|
| Baseline | |||
| DAS28-CRP score <3.2 | 113 (93) | 53 (90) | - |
| DAS28-CRP score <2.6 | 92 (76) | 48 (81) | - |
| 2011 ACR/EULAR Boolean based remission | 31 (26) | 21 (36) | - |
| 9 month follow-up | |||
| DAS28-CRP score <3.2 | 89 (74) | 54 (92) | 0.005 |
| DAS28-CRP score <2.6 | 73 (60) | 48 (81) | 0.005 |
| 2011 ACR/EULAR Boolean based remission | 22 (18) | 17 (29) | 0.104 |
| 18 month follow-up | |||
| DAS28-CRP score <3.2 | 103 (85) | 53 (90) | 0.464 |
| DAS28-CRP score <2.6 | 86 (71) | 47 (80) | 0.218 |
| 2011 ACR/EULAR Boolean based remission | 29 (24) | 24 (41) | 0.021 |
Data are number (%) of patients. ACR/EULAR=American College of Rheumatology/European League Against Rheumatism.
*χ2, crude estimates without adjustments.